Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Receivables - Other: 2021-2024

Historic Receivables - Other for ARS Pharmaceuticals (SPRY) over the last 4 years, with Dec 2024 value amounting to $1.2 million.

  • ARS Pharmaceuticals' Receivables - Other rose 2708.55% to $4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year increase of 2708.55%. This contributed to the annual value of $1.2 million for FY2024, which is 88.96% up from last year.
  • As of FY2024, ARS Pharmaceuticals' Receivables - Other stood at $1.2 million, which was up 88.96% from $652,000 recorded in FY2023.
  • ARS Pharmaceuticals' 5-year Receivables - Other high stood at $1.2 million for FY2024, and its period low was $159,000 during FY2021.
  • Its 3-year average for Receivables - Other is $699,000, with a median of $652,000 in 2023.
  • Data for ARS Pharmaceuticals' Receivables - Other shows a peak YoY spiked of 206.10% (in 2023) over the last 5 years.
  • Yearly analysis of 4 years shows ARS Pharmaceuticals' Receivables - Other stood at $159,000 in 2021, then skyrocketed by 33.96% to $213,000 in 2022, then skyrocketed by 206.10% to $652,000 in 2023, then surged by 88.96% to $1.2 million in 2024.